Market Overview

UPDATE: Stifel Nicolaus Raises PT to $40 on Theravance on Improved Risk Profile

Related THRX
Barron's Recap: Ready To Wear?
UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

Stifel Nicolaus reiterated its Buy rating on Theravance (NASDAQ: THRX) and raised its price target from $28 to $40.

Stifel Nicolaus noted, "We believe recently-announced top-line P3 LAMA/LABA data implies a relatively clear regulatory path forward and our physician conversations suggest the utilization of these combined mechanisms of action should gain considerable traction/adoption in those moderate/severe COPD patients whom require prolonged/significant bronchodilation."

Therevance closed at $29.49 on Friday.

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (THRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters